文献速递胸部肿瘤

IV期驱动基因阳性肺腺癌患者血清肿瘤标志物的基线与治疗中特征

Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
PubMed 文献 · J Thorac Oncol · 2017-08-24

单中心回顾性分析142例IV期肺腺癌患者(ALK重排60例、EGFR突变50例、ROS1重排4例、KRAS突变29例)基线与治疗中CEA、CA125、CA19.9、CA27.29水平。82%患者至少一项标志物升高(四项全测时为95%),CA27.29最常见升高、CA19.9最少见;仅CA27.29在不同驱动基因间有显著差异(KRAS中较少见,p=0.016)。EGFR与ALK患者TKI治疗中标志物降至谷值的中位时间分别为16.4周与20周;41例EGFR/ALK/ROS1患者中24例(59%)在TKI治疗前4周内出现初始升高,其中58%随后降至基线以下;53%的系统性进展与22%的单纯中枢神经系统进展出现较谷值升高≥10%。

要点

  • IV期肺腺癌无论驱动基因如何,血清肿瘤标志物常升高,CA27.29最常见升高、CA19.9最少见。
  • EGFR与ALK患者TKI治疗中标志物降至谷值的中位时间分别为16.4周与20周。
  • 治疗前4周内标志物变化可能误导判断;进展常伴标志物升高,非中枢神经系统部位更明显。

核心结论

  • 血清肿瘤标志物在肺腺癌中常升高,与驱动基因无关;治疗前4周内的变化可能误导判断;进展与标志物升高相关,尤其是中枢神经系统以外的部位。

研究设计与样本

  • 单中心回顾性分析,纳入142例IV期肺腺癌患者,按驱动基因分组:ALK重排60例、EGFR突变50例、ROS1重排4例、KRAS突变29例,分析基线及治疗中CEA、CA125、CA19.9、CA27.29水平。

主要发现

  • 82%的患者至少一项标志物升高(四项标志物全测时为95%),CA27.29最常见升高、CA19.9最少见。
  • 仅CA27.29在不同驱动基因间差异显著(KRAS中较少见,p=0.016)。
  • EGFR与ALK患者TKI治疗中标志物降至谷值的中位时间分别为16.4周与20周。
  • 41例EGFR突变或ALK/ROS1重排患者中,24例(59%)在TKI治疗前4周内出现初始升高,其中58%随后降至基线以下。
  • 标志物较谷值升高≥10%见于53%的系统性进展和22%的单纯中枢神经系统进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The role of serum tumor markers in the modern management of advanced NSCLC remains poorly described. METHODS: A single-center retrospective analysis of available carcinoembryonic antigen, CA125, CA19.9, and CA27.29 levels at baseline and during treatment of stage IV lung adenocarcinoma by oncogenic driver was conducted. RESULTS: A total of 142 patients were analyzed (60 with anaplastic lymphoma kinase gene [ALK] rearrangement, 50 with EGFR mutation, four with ROS1 rearrangement, and 29 with KRAS mutation). Of these, 82% had at least one marker (95% if all four markers were measured), with CA27.29 being the most commonly increased and CA19.9 the rarest. Only CA27.29 differed significantly by oncogene (it was less common in KRAS) (p = 0.016). The median times to nadir during tyrosine kinase inhibitor (TKI) therapy in EGFR and ALK cases were 16.4 and 20 weeks, respectively. Of the 41 patients with EGFR mutation or ALK or ROS1 rearrangement, 24 (59%) demonstrated an initial increase within the first 4 weeks of TKI therapy, 58% of whom then had their levels fall below baseline. An increase in marker level of 10% or more from nadir occurred in 53% of systemic and 22% of central nervous system-only progression. CONCLUSIONS: Serum tumor markers are frequently increased in lung adenocarcinoma regardless of driver oncogene. Changes within the first 4 weeks of therapy may be misleading. Progression is associated with marker increases, especially in sites other than the central nervous system.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Noonan SA, Patil T, Gao D, et al. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol. 2017. PMID: 28843358. doi:10.1016/j.jtho.2017.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。